ABSTRACT
What is known about this subject?
Psychotropic medications are commonly associated with anticholinergic side effects. In susceptible patients, this can precipitate angle closure resulting in permanent vision loss.
What new information is offered in this case study?
Several psychotropic medications are of higher risk than others in susceptible patients. Patients can also remain asymptomatic until advanced glaucoma is present.
What are the implications for research, policy, or practice?
Identification of high risk patients and either having them formally assessed or managing them with a psychotropic medication with minimal anticholinergic effects can avoid this complication.
Background
Angle closure secondary to psychotropic medications is a rare, but important, presentation which must be considered when prescribing psychotropic medications. Patients who develop angle closure may present symptomatically or asymptomatically. Both acute and chronic angle closure can lead to permanent visual dysfunction or loss due to glaucoma, if not managed appropriately.
With the increasing burden of mental health, 1 it is pertinent that all prescribing physicians are aware of this adverse effect that is related predominantly to the anticholinergic side-effects of psychotropic medications. Prescribing physicians should be able to identify patients in the highest risk groups and either have them formally assessed by an ophthalmologist or optometrist prior to prescribing or choose a psychotropic with minimal anticholinergic sideeffects.
Case details
A 35-year-old year Caucasian female was referred to an ophthalmologist with intermittent blurred vision associated with haloes in her left eye for one month. She had no history of spectacles and relevant medical history included postnatal depression of 13 years duration managed initially with fluvoxamine 50mg daily switched to quetiapine 100mg nightly for 3 months prior to her presentation.
Examination showed a visual acuity of 6/6 (right) and 6/12 (left) with mild corneal oedema on the left. She also demonstrated bilateral high intraocular pressures (IOP) by Goldmann applanation tonometry measuring 34mmHg (right) and 51mmHg (left) (normal 10-21mmHg). 
Discussion
This case demonstrates secondary angle closure glaucoma from systemic psychotropics. The presentation of blurred vision associated with haloes around lights is classic for a patient who has had an acute change in IOP. This results in corneal oedema which subsequently presents as haloes around lights. The eye is often painful, injected and has a fixed mid-dilated pupil that may be unresponsive to light however more commonly and as evidenced by the right eye, patients can be asymptomatic. 3 The mechanism by which this occurs is predominantly due to their anticholinergic effects, resulting in mydriasis, forward displacement of the lens-iris diaphragm and ciliary body swelling. 4, 5 Combined, these anatomical changes can occlude the trabecular meshwork, blocking drainage of aqueous humour with a subsequent increase in IOP. The incidence of psychotropic induced angle closure however is likely very low. To our knowledge, no incidence rate has been reported in the literature. However, ophthalmic mydriatic agents have been shown to induce acute angle closure in 0.03 per cent of 6,760 patients in a Caucasian population from the Netherlands. 6 The observed baseline incidence of narrow angles (predisposing the patient to angle closure) was 2.2 per cent in that cohort. Other cohorts may have higher rates of narrow-angles. For example, in a Vietnamese study it was found to be 8.5 per cent. 7 With the increasing population of Asian migrants in Australia, it is likely that our prevalence of narrow angles will be higher than that observed in the Netherlands cohort. Furthermore, the use of psychotropic medications is increasing. A study from 2012 found a 58.2 per cent rise between 2000 and 2011, 1 so it is likely that we will see increasing presentations of psychotropic induced angle closure if this trend continues.
Typical medications associated with this phenomenon include medication classes: tricyclic antidepressants (TCAs), antipsychotics, selective-serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs) and benzodiazepines. 4, [8] [9] [10] [11] [12] The highest risk classes are the TCAs and some second generation antipsychotics (SGAs) as they have the greatest anticholinergic effects. 4, 8, 9 The risk profile of drugs in the other classes varies depending on their potency at the various receptors (Table 1) . 4, 9 Serotonergic effects implicated in angle closure occur as a result of lensiris diaphragm displacement and relaxation of sphincter pupillae 4,9 and adrenergic effects implicated occur by direct action on dilator pupillae resulting in mydriasis. 4 Medications alone are typically not enough to cause angle closure. Patients will often have other risk factors such as significant hypermetropia (long-sightedness), being of Asian descent, being female and having personal or family history of angle closure or angle closure glaucoma. 4, 5, 8, 13 These patients are predisposed to narrow angles and shallow ACs and are at higher risk. In these patients it is recommended that screening be undertaken by an ophthalmologist or optometrist prior to commencement of such medications.
Peripheral iridotomies will minimise any pupil block and anterior bowing of the iris but will not prevent anterior displacement of the lens-iris diaphragm. In these patients psychotropics with the least anticholinergic effects (e.g., melatonergic antidepressants, as in this case) should be considered.
Patients identified as having an episode of acute angle closure require prompt assessment by an ophthalmologist as high IOPs can rapidly cause permanent vision-loss secondary to damage of the optic-nerve (GON). In this scenario management varies depending on the aetiology of the angle closure however typically includes acutereduction of the IOP through means of topical antiglaucoma eye-drops (e.g., beta-blockers, alpha-agonists), topical miotic agents where indicated, e.g., pilocarpine), systemic-medications (e.g., acetazolamide, mannitol) and interventional-procedures (e.g., indentation-gonioscopy, Nd:YAG-laser peripheral-iridotomies, AC-paracentesis). 3, 14, 15 If the symptoms are medication related the offending agent should be stopped where possible. Where medically necessary definitive ophthalmic intervention (e.g., lensectomy) could be considered and may facilitate continuation of the particular causative medication.
Aside from enquiring about risk factors one method to screen for these patients is an in-office screening test done by shining a penlight parallel to the iris from the temporal side can help identify patients at risk (Figure 3) . 4, 8, 16 If the entire iris is illuminated the angle of the anterior chamber is likely open 4 and the patient at reduced risk. This method of screening was found to have a sensitivity of 94 per cent and specificity or 67 per cent from two non-ophthalmologist doctors in a study of 45 patients from Brazil. 16 However another study of 96 patients in India had a sensitivity of 45.5 per cent and a specificity of 82.7 per cent, 17 suggesting that reliability is operator dependent so judicious caution must be advised and the findings considered in context of the patient's history and risk factors. This recommendation was mirrored in a controlled Chinese study of 1,405 subjects in 2007. 18 Despite the utility and novelty of this test it should be noted that this is not a substitute for slit-lamp examination with gonioscopy performed by ophthalmologists or optometrists which remains the definitive method of risk assessment.
Conclusion
In conclusion, it is prudent that prescribers of the above medications are aware for potential angle closure and symptoms associated with this including decreased visual acuity, haloes around lights, intermittent pain, photophobia and visual field changes. Patients with these symptoms require urgent ophthalmological assessment and management to prevent permanent vision-loss. Patients at increased risk of angle closure especially those with hypermetropia (long-sightedness) or a personal/family history of angle closure, or patients with another visual risk factor such as only one good eye, should be referred to an ophthalmologist or optometrist for assessment of their risk prior to commencing treatment. Alternatively these patients could be considered for treatment with medications with reduced ocular side-effects however we acknowledge that this may not always be easy and that the use of a particular psychotropic can be very necessary and even life-saving. For patients on higher risk medications we recommend regular discussion with patients at follow-up visits about any visual symptoms they may have experienced and education on the symptoms to be vigilant of, such as blurred vision, haloes, ocular pain and photophobia. 
